Abstract
We thank Drs. Mishra and Singh for their interest in our paper1 in which seladelpar, a potent and selective PPARδ agonist, demonstrated dose-dependent improvements in markers of cholestasis and inflammation1 and would like to clarify the 4 issues that they raised.2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
